IsoPlexis    

Branford,  CT 
United States
http://isoplexis.com

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers. Visit isoplexis.com to learn more.


 Press Releases

  • IsoPlexis today announced that its IsoSpark system has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group. 

    The breakthrough IsoSpark platform is a critical tool that provides new and accessible layers of biological data at the single-cell level, and the ability to interrogate the secreted proteome, the phosphoproteome, and the metabolome from single cells for the first time. This allows researchers to connect more deeply to in vivo biology, and predict complex responses to therapies and disease in cancer immunotherapy, cell and gene therapy, COVID-19, autoimmune disease, and many other areas.

    "More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy and comfortable," said Maria Jimenez, Chief Operating Officer of the Business Intelligence Group. "We are thrilled to be honoring IsoPlexis as they are one of the organizations leading this charge and helping humanity progress."

    "We are very excited that our IsoSpark system was recognized by BIG as a top innovation of 2021. We are now expanding access to insights at the convergence of single-cell biology and proteomics with our revolutionary benchtop system accessible by any lab. The IsoSpark system allows for acceleration in key critical areas of life sciences research, paving the way for personalized, curative medicines," said Sean Mackay, IsoPlexis' Co-Founder and CEO.

    Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were then judged by a select group of business leaders and executives who volunteer their time and expertise to score submissions.

    ABOUT ISOPLEXIS:

    IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers. Visit http://www.isoplexis.com to learn more.

    ABOUT BUSINESS INTELLIGENCE GROUP:

    The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.

    CONTACT:

    Jon Chen 
    VP of Marketing 
    IsoPlexis
    press@isoplexis.com

    Maria Jimenez
    Chief Operating Officer
    Business Intelligence Group
    jmaria@bintelligence.com
    +1 (909) 529-2737

  •  IsoPlexis today announced that it has been named by Fierce Medtech as one of 2020's Fierce 15, designating it as one of the most promising private companies in the industry. 

    IsoPlexis, the leader in functional single-cell proteomics, provides crucial tools to researchers, enabling them to access new layers of biological data at the single-cell level to connect more deeply to in vivo biology and predict complex responses to therapies and diseases in cancer immunotherapy, cell and gene therapy, COVID-19, autoimmune diseases, and many other areas.

    "We are honored to be recognized as a Fierce 15 company by Fierce Medtech," said CEO and Co-Founder of IsoPlexis, Sean Mackay. "We are on a mission to leverage our powerful single cell proteomic biology to accelerate a wide array advanced, curative medicines. Our team and user base have grown significantly over the past year, and we are looking forward to drive more exciting breakthroughs as we scale."

    The Fierce 15 celebrates the spirit of being "fierce" — championing innovation and creativity, even in the face of intense competition.  This is Fierce Medtech's 9th annual Fierce 15 selection. This year's full list of winners can be viewed online at https://www.fiercebiotech.com/special-report/fierce-medtech-s-2020-fierce-15.

    "Each member of this year's class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic," said Conor Hale, associate editor of Fierce Medtech.

    An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day's top stories. Every year Fierce Medtech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

    About Fierce Medtech
    Fierce Medtech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology.  More than 90,000 top industry professionals rely on Fierce Medtech for an insider briefing on the day's top stories.

    About IsoPlexis
    IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies and by 45% of comprehensive cancer centers. Visit http://www.isoplexis.com to learn more.

    CONTACTS:

    Rebecca Willumson
    Fierce Medtech
    202-824-5050
    rwillumson@questex.com

    Jon Chen 
    VP of Marketing 
    IsoPlexis
    press@isoplexis.com


 Products

  • IsoSpark
    The IsoSpark is a personalized functional proteomics system for every lab. Accelerate personalized medicine across research areas & high-impact applications, all in one intuitive system that fits on any lab bench....

  • The IsoSpark is a personalized functional proteomics system for every lab. Accelerate personalized medicine across research areas & high-impact applications, all in one intuitive system that fits on any lab bench. Across all applications, discover direct functional profiling of single-cell and bulk population insights with walk-away automation. 
  • IsoLight
    Automate your entire workflow with the IsoLight system. The IsoLight's innovative and impactful end-to-end workflow covers a wide range of applications, from early optimization to applying key, correlative insights and visualizations....

  • Automate your entire proteomics workflow with one system in a walk-away manner. The IsoLight is a hub for comprehensive proteomic profiling of each cell type across a large assay menu of single-cell and population chip and software products. With one instrument and companion analysis software, achieve functional immune profiling at single-cell level, analyze intracellular signaling omics, and run high-plex automated immunoassays. The entire multiplexed ELISA workflow is completely automated and handsoff to allow maximum laboratory multitasking. Just add your sample and walk away, achieving fully analyzed data on the same day. No more ELISA washing and incubation stations, no centrifuge, no vortexer, and no plate reader. All of your proteomic needs are integrated into the completely automated IsoLight system.
  • IsoSpeak Software
    IsoSpeak is the first automated informatics suite for advanced, functional, cellular mapping and visualizations which can reveal correlative insights into true, functional immune biology....

  • IsoSpeak is the first automated informatics suite for advanced, functional, cellular mapping and visualizations which can reveal correlative insights into true, functional immune biology. IsoSpeak’s push-button user interface and advanced automation allows users to visualize, target, and utilize data from direct functional proteomic profiling of single cells and bulk populations.